Celecoxib improves disease-free and overall survival in ctDNA-positive stage III colon cancer patients when combined with ...

Japanese patients with vitiligo experienced lower quality of life and higher levels of anxiety and depression, especially when the disease affected their social life or had relapsed, according to a ...

The Managed Healthcare Executive 2025 State of the Industry survey is a timely snapshot of how payers, providers and pharmacy ...

In another first, Sandoz launched in November 2025 the first FDA-approved biosimilar of Tysabri (natalizumab). Tyruko (natalizumab-sztn) is used to treat adult patients with relapsing multiple ...

Teledermatology's growth in 2025 improved efficiency and accessibility, with virtual visits reducing costs and saving time for patients and doctors. Hybrid models combining live video and photo ...